Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Standardisation of Measurements in Exhaled Breath and Exhaled Breath Condensate.

NCT00983671

Asthma Cystic Fibrosis Chronic Lung Disease +1 more

UNKNOWN

Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis

NCT03643263

Bronchiectasis

COMPLETED

Mucus Solids Concentration in Patients With Bronchiectasis

NCT04310618

Bronchiectasis

UNKNOWN

Exhaled Breath Condensate (EBC) Assessment in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT00448500

Chronic Obstructive Pulmonary Disease

COMPLETED

Assessment of an Exhaled Breath Test to Detect Bronchiectasis

NCT05293314

Bronchiectasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like Cystic fibrosis (CF) or Bronchial asthma (AB) would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchial Asthma Pulmonary Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asthma

Children/adults with moderate or IgE mediated asthma with inhaled and/or food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment.

Collection of breath condensate

Intervention Type DIAGNOSTIC_TEST

Breath condensate will be collected from the patients involved in study.

Cystic fibrosis

Children/adults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration.

Collection of breath condensate

Intervention Type DIAGNOSTIC_TEST

Breath condensate will be collected from the patients involved in study.

Healthy control

Healthy control children/adults without chronic or autoimmune disease

Collection of breath condensate

Intervention Type DIAGNOSTIC_TEST

Breath condensate will be collected from the patients involved in study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collection of breath condensate

Breath condensate will be collected from the patients involved in study.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children/adults with moderate or IgE mediated asthma
* Children/adults with cystic fibrosis
* Healthy control children/adults without lung disorders